Cargando…
Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review
Glioblastoma (GBM) is the most common primary brain tumor. Despite aggressive treatment, GBM almost always recurs. The current standard-of-care for treatment of newly diagnosed GBM has remained relatively unchanged since 2005: maximal safe resection followed by concomitant chemoradiation (CRT) with...
Autores principales: | Fabian, Denise, Guillermo Prieto Eibl, Maria del Pilar, Alnahhas, Iyad, Sebastian, Nikhil, Giglio, Pierre, Puduvalli, Vinay, Gonzalez, Javier, Palmer, Joshua D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406491/ https://www.ncbi.nlm.nih.gov/pubmed/30717372 http://dx.doi.org/10.3390/cancers11020174 |
Ejemplares similares
-
Prognostic implications of epidermal and platelet-derived growth factor receptor alterations in 2 cohorts of IDHwt glioblastoma
por: Alnahhas, Iyad, et al.
Publicado: (2021) -
An evaluation of MGMT promoter methylation within the methylation subclasses of glioblastoma
por: Alnahhas, Iyad, et al.
Publicado: (2020) -
Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis
por: Alnahhas, Iyad, et al.
Publicado: (2020) -
Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis
por: Alnahhas, Iyad, et al.
Publicado: (2021) -
Mitochondrial DNA Alterations in Glioblastoma (GBM)
por: Leão Barros, Mariceli Baia, et al.
Publicado: (2021)